Multiparametric Monitoring of Early Response to Antiangiogenic Therapy: A Sequential Perfusion CT and PET/CT Study in a Rabbit VX2 Tumor Model

Figure 2

Averaged (a) BF, (b) BV, and (c) PS before and at different time points after bevacizumab therapy. In the control group, BF increased gradually and both BF and BV on day 14 demonstrated significant increases. In the treatment group, a significant decrease in BV on day 3 was observed. is significant change compared to the baseline, BF is blood flow, BV is blood volume, and PS is permeability surface area product.

(a)

(b)

(c)